Welcome to our dedicated page for Accuray Incorp SEC filings (Ticker: ARAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Accuray Incorporated filings document financial results, Regulation FD presentations, governance changes, and material agreements for a radiation therapy systems company. Recent 8-K reports cover quarterly operating results, withdrawal of financial guidance, investor presentation materials, executive appointments and departures, consulting and separation arrangements, and equity-based compensation matters.
The filing record also includes formal disclosure controls and reporting-status matters, including a Form 12b-25 late 10-Q notification and non-reliance disclosures related to remaining performance obligation, or RPO, presentation in revenue footnotes. These filings connect Accuray's public-company reporting to revenue disclosure methodology, audit committee determinations, executive compensation terms, and corporate governance events.
Accuray Incorporated amended its Consulting Agreement with Dedication Capital, LLC, an affiliate of director Steven F. Mayer. The amendment cuts by 50% the base consulting fee after March 31, 2026 through October 31, 2026 and reduces the minimum cash incentive amounts for the fiscal year ended June 30, 2026 and the fiscal quarter ended September 30, 2026. In exchange, time-based vesting was accelerated as of April 1, 2026 for 916,336 Initial Restricted Shares and all PSAs, while the remaining 333,004 Initial Restricted Shares vest on October 31, 2026. The changes are expected to generate at least $362,500 in cash savings for the company.
Accuray Incorporated has appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026, as disclosed in a press release furnished under Regulation FD. He joins the executive leadership team to lead the company’s global commercial organization across sales, marketing, pricing, and market access.
The company highlights his prior success driving commercial turnarounds and double-digit annual sales growth in complex medical technology businesses. Accuray frames the hire as part of its ongoing transformation, aiming to strengthen commercial execution, grow systems and services sales, and enhance long-term value creation.
Accuray Inc SVP tax-withholding share disposition
Accuray Inc executive Sandeep Chalke, the SVP and Chief Commercial Officer, reported a tax-related share disposition. On this Form 4, 40,000 shares of Common Stock were withheld by the company at an implied price of $0.3881 per share to cover tax obligations tied to RSU vesting.
These shares were not sold in the open market but used to satisfy tax withholding and remittance requirements in a net settlement of restricted stock units. After this transaction, Chalke directly holds 419,806 shares of Accuray Inc common stock.
The Vanguard Group files an amendment (Schedule 13G/A) reporting 0 shares of Accuray Inc common stock. The amendment states Beneficial Ownership as 0 shares and 0% of the class as of 03/13/2026 and is signed on 03/26/2026.
The filing explains that on 01/12/2026 Vanguard completed an internal realignment and its subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538; Vanguard states it no longer has beneficial ownership over securities held by those subsidiaries/divisions.
Accuray Incorporated entered into a separation agreement with Senior Vice President and Chief Commercial Officer Sandeep Chalke on March 13, 2026, ahead of his previously disclosed departure effective March 31, 2026. The agreement grants vesting of equity awards scheduled to vest on May 31, 2026, with all later equity forfeited. Mr. Chalke will receive a lump-sum cash payment of $459,000, equal to 12 months of base salary, plus a pro‑rated fiscal 2026 bonus paid on the same schedule as other executives. These benefits replace any prior severance or noncompetition payments, and the agreement, which includes a general release of claims, becomes effective after a seven‑business‑day revocation period.
Accuray SVP and COO Leonel Peralta reported equity compensation transactions involving restricted stock units and common stock. On February 28, 2026, he exercised 83,723 restricted stock units, receiving the same number of common shares at $0.00 per share. To satisfy tax withholding obligations related to this net settlement, 28,969 common shares were withheld by the company at $0.55 per share, as described in the footnote. After these transactions, Peralta directly owned 54,754 shares of Accuray common stock.
Accuray Incorporated filed a prospectus registering 7,000,516 shares of common stock for resale by selling stockholders, representing shares issuable upon exercise of warrants issued under a Loan Amendment. The prospectus states the company will not receive proceeds from resale but will receive proceeds from any cash exercise of the warrants.
The registered shares consist of 3,062,726 Super Premium, 2,187,661 Premium and 1,750,129 Penny warrant-based shares. Shares outstanding were 118,782,630 as of January 30, 2026. Exercise periods run through December 15, 2032 for the Loan Amendment warrants.
Accuray Inc. director Steven F. Mayer purchased 54,875 shares of Accuray common stock in an open-market transaction on February 20, 2026. The shares were bought at a weighted-average price of $0.5627 per share, with individual trade prices ranging from $0.5334 to $0.5897. Following this purchase, Mayer directly owns 1,545,620 shares of Accuray common stock.
Accuray Inc. director Steven F. Mayer reported open-market purchases of the company’s common stock. He bought 126,125 shares on February 18, 2026 at a weighted average price of $0.5328 per share and 69,000 shares on February 19, 2026 at a weighted average price of $0.5304 per share. These transactions increased his direct holdings to 1,490,745 shares of Accuray common stock.